Tech Company Financing Transactions

Veracyte Funding Round

On 6/28/2013, Veracyte received $28 million in Series C funding from Domain Associates, GE Ventures and jVen Capital.

Transaction Overview

Company Name
Veracyte
Announced On
6/28/2013
Transaction Type
Venture Equity
Amount
$28,000,000
Round
Series C
Investors

Domain Associates (Jesse Treu)

GE Ventures

jVen Capital (Evan Jones)

Kleiner Perkins Caufield & Byers (Brook Byers)

TPG Biotech (Fred Cohen)

Versant Ventures (Samuel Colella)

Proceeds Purpose
This funding will help Veracyte expand availability of our Afirma Thyroid FNA Analysis to help more patients with inconclusive thyroid nodule fine needle aspiration (FNA) biopsy results potentially avoid unnecessary thyroid surgery. This additional capital will also support our investment in research and development of new products similarly designed to help patients avoid unnecessary invasive procedures, while reducing healthcare costs.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
6000 Shoreline Ct. 300
San Francisco, CA 94080
USA
Phone
(650) 243-6300
Website
www.veracyte.com
Email Address
[email protected]
Overview
Veracyte (NASDAQ: VCYT) is pioneering the emerging field of molecular cytology. We are developing molecular tests designed to improve the diagnostic accuracy of cytology samples, thereby helping to increase the utility of these minimally invasive procedures as an alternative to surgical biopsy.
Profile
Veracyte LinkedIn Company Profile
Social Media
Veracyte Company Twitter Account
Company News
Veracyte News
Facebook
Veracyte on Facebook
YouTube
Veracyte on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Bonnie Anderson
  Bonnie Anderson LinkedIn Profile  Bonnie Anderson Twitter Account  Bonnie Anderson News  Bonnie Anderson on Facebook
Chief Financial Officer
Giulia Kennedy
  Giulia Kennedy LinkedIn Profile  Giulia Kennedy Twitter Account  Giulia Kennedy News  Giulia Kennedy on Facebook
Chief Information Officer
Ashish Kheterpal
  Ashish Kheterpal LinkedIn Profile  Ashish Kheterpal Twitter Account  Ashish Kheterpal News  Ashish Kheterpal on Facebook
Chief Operating Officer
Christopher Hall
  Christopher Hall LinkedIn Profile  Christopher Hall Twitter Account  Christopher Hall News  Christopher Hall on Facebook
Chief Scientific Officer
Giulia Kennedy
  Giulia Kennedy LinkedIn Profile  Giulia Kennedy Twitter Account  Giulia Kennedy News  Giulia Kennedy on Facebook
VP - Bus. Development
John Hanna
  John Hanna LinkedIn Profile  John Hanna Twitter Account  John Hanna News  John Hanna on Facebook

 

 

Browse more venture capital transactions:

Prev: 6/28/2013: Middle Peak Medical venture capital transaction
Next: 6/28/2013: Blaze Bioscience venture capital transaction

 

Share this article

 

News on VC Transactions

We do our best to report on all VC transactions involving tech companies. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.